Anatomic pathology selected abstracts

written by CAP TODAY
June 18, 2025

June 2025—Transbronchial cryobiopsies are increasingly used to diagnose interstitial lung disease, but published information on the features of specific manifestations of ILD in cryobiopsies is lacking. Therefore, the authors sought to provide pathologic guidelines for separating usual interstitial pneumonia (UIP) of idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis (FHP), and connective tissue disease-associated interstitial lung disease (CTD-ILD) in cryobiopsies. They examined 120 cryobiopsies from patients with CTD-ILD established via multidisciplinary discussion and compared them with a prior series of 121 biopsies from patients with IPF or FHP also established via multidisciplinary discussion. A nonspecific interstitial pneumonia (NSIP) pattern alone was seen in 36 of 120 (30 percent) CTD-ILD, three of 83 (3.6 percent) FHP, and two of 38 (5.2 percent) IPF cases, statistically favoring a diagnosis of CTD-ILD.

Molecular pathology selected abstracts

written by CAP TODAY
June 18, 2025

June 2025—Comprehensive molecular profiling and DNA methylation classification have become critical for diagnosing and managing central nervous system tumors. However, workflows for molecular testing of these tumors are often limited by the cost of equipment and reagents, technical complexity, and lengthy turnaround times. The wide range of alterations that can be present, including *MGMT* promoter methylation, single nucleotide variants, insertions or deletions (indels), copy number variants, and fusions and structural variants, often necessitate the use of multiple assays for a complete molecular workup. All of these factors have led to a growing demand for molecular assays that are faster, more comprehensive, and more accessible. Recognizing this need, the authors had previously conducted a proof-of-concept study of an adaptive sampling-based nanopore sequencing workflow platform, called Rapid-CNS^2, that they had developed.

Newsbytes

written by CAP TODAY
June 18, 2025

June 2025—Whether it's easier to edit a document created by another source or create more or less the same document from scratch is open to debate. But clinical informaticians at Stanford Health Care, Palo Alto, Calif., are banking on clinicians preferring to assess and adjust versus starting with a blank page. Therefore, the health care system has been conducting trials on the use of generative artificial intelligence to draft patient-centric interpretations of pathology test results that these care providers can review and edit and then share with patients.

Q&A column

written by CAP TODAY
June 18, 2025

June 2025
Q. Our institution performs rapid onsite evaluation (ROSE). In cases in which multiple passes are done, we frequently encounter unsatisfactory specimens (debris, neutrophils, bronchial cells, etc.). These cases are rescreened by a cytotechnologist and pathologist. If the case goes to a different pathologist, those unsatisfactory slides are unnecessarily screened three times. They're also included in the daily slide workload of the cytotechnologist. Can the onsite pathologist dispose of unsatisfactory Diff-Quik slides and keep just the counter formalin-fixed slides? Since ROSE is provided for that episode, can you comment on billing? Read answer.

Q. Many times a platelet count on an automated hematology system indicates some degree of thrombocytopenia or the analyzer reports a high mean platelet volume or platelet large cell ratio, while a blood smear shows large platelets and/or giant platelets. Is it OK to include a comment in the report that the platelets are adequate or that the count could be due to large platelets, especially with values that indicate marked thrombocytopenia? Read answer.

Put It on the Board

written by CAP TODAY
June 18, 2025

June 2025—A Labcorp survey of more than 100 genetic counselors, including 15 hours of one-one-one conversations, found their three pain points to be balancing patient care and administrative demands, the financial difficulties that complex genetic testing presents, and staying on top of scientific and technologic advances in genetics. Of the time constraints, one genetic counselor at a large health system said, “Anything a lab partner can do, from making their portal easier to get reports or having easy access to someone on their end to help me with some questions, all that gives me more time with the patient.”

Letters

written by CAP TODAY
June 18, 2025

June 2025—I was encouraged to read the CAP TODAY articles on *DPYD* testing ("Time for wider pretreatment *DPYD* genotyping?" December 2024; "*DPYD* genotyping assays—what's recommended and why," January 2025). I lost my mother not to her cancer but to a known and preventable toxicity from 5-fluorouracil (5-FU) chemotherapy. She was never informed of the risks of 5-FU if one is DPD deficient nor was she tested for DPD deficiency, a genetic condition that impairs the body's ability to break down 5-FU and capecitabine. Within days of starting treatment, she developed devastating toxicity that ultimately took her life. We had no warning. Only after she was suffering in the hospital from 5-FU toxicity did I learn about *DPYD* testing, which could have spared her horrific pain and saved her life. My mom was so easy to live with and so hard to live without. We continue to be heartbroken that her golden years were cut short.

StaffReady launches mobile app, website

written by CAP TODAY
June 18, 2025

June 17, 2025—StaffReady has released a mobile app for its StaffReady Scheduling.

Proscia releases laboratory leadership report

written by CAP TODAY
June 18, 2025

June 16, 2025—Proscia has published a report in which it partnered with the Dark Intelligence Group to

survey more than 360 senior professionals representing independent, hospital, and academic laboratories.

FDA clears Sysmex CN-6000 automated blood coag analyzer

written by CAP TODAY
June 18, 2025

June 13, 2025—Sysmex America has received FDA clearance for its CN-6000 automated blood coagulation analyzer.

Seegen to unveil Cureca PCR solution at ADLM 2025

written by CAP TODAY
June 18, 2025

June 12, 2025—Seegene will unveil Cureca, a next-generation system designed to streamline automation in polymerase chain reaction testing, on July 30 at ADLM 2025, in Chicago (July 27–31).